Alpa Parikh - Lumos Pharma Senior Management
Executive
Alpa Parikh is Senior Management of Lumos Pharma
| Phone | 512 215 2630 |
| Web | https://lumos-pharma.com |
Lumos Pharma Management Efficiency
The company has return on total asset (ROA) of (0.6964) % which means that it has lost $0.6964 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7283) %, meaning that it created substantial loss on money invested by shareholders. Lumos Pharma's management efficiency ratios could be used to measure how well Lumos Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Lumos Pharma currently holds 585 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Lumos Pharma has a current ratio of 17.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Lumos Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Douglas CPA | Century Therapeutics | N/A | |
| Stephen JD | Shattuck Labs | 50 | |
| Suresh Silva | Shattuck Labs | N/A | |
| Chad Cowan | Century Therapeutics | N/A | |
| Daron Evans | Rezolute | 50 | |
| Erin OBoyle | Rezolute | N/A | |
| Arthur Hanson | Champions Oncology | N/A | |
| Esq JD | Erasca Inc | 52 | |
| Robert Shoemaker | Erasca Inc | 44 | |
| Michael Varney | Erasca Inc | 67 | |
| Karin Heidemann | Champions Oncology | N/A | |
| Michael Naso | Century Therapeutics | N/A | |
| Marianna Zipeto | Champions Oncology | N/A | |
| Thomas PharmD | Shattuck Labs | N/A | |
| Kelli MS | Shattuck Labs | N/A | |
| MS MBA | Rezolute | 51 | |
| Michael Covarrubias | Rezolute | N/A | |
| Daniel George | Anebulo Pharmaceuticals | 55 | |
| Nick MD | Century Therapeutics | N/A | |
| Conor CPA | Shattuck Labs | N/A | |
| Michael MD | Century Therapeutics | 53 | |
Management Performance
| Return On Equity | -1.73 | |||
| Return On Asset | -0.7 |
Lumos Pharma Leadership Team
Elected by the shareholders, the Lumos Pharma's board of directors comprises two types of representatives: Lumos Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lumos. The board's role is to monitor Lumos Pharma's management team and ensure that shareholders' interests are well served. Lumos Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lumos Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Hawkins, CEO Chairman | ||
| Lori CPA, CFO Officer | ||
| MD BA, Chief Officer | ||
| Lisa Miller, Director Relations | ||
| John McKew, Chief President | ||
| Bradley JD, Chief Counsel | ||
| Carl Langren, Consultant | ||
| BBA CPA, Chief Officer | ||
| MD FAAP, Chief Officer | ||
| Alpa Parikh, Senior Management | ||
| Eddie MBA, Corporate Controller |
Lumos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lumos Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.73 | |||
| Return On Asset | -0.7 | |||
| Operating Margin | (10.52) % | |||
| Current Valuation | 24.19 M | |||
| Shares Outstanding | 8.65 M | |||
| Shares Owned By Insiders | 32.69 % | |||
| Shares Owned By Institutions | 24.27 % | |||
| Number Of Shares Shorted | 54.33 K | |||
| Price To Earning | (2.37) X | |||
| Price To Book | 7.64 X |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Lumos Stock
If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |